



**BRAWN**



49558

CIN NO.: L74899DL1985PLC022468

To,

Date: 29-05-2017

The Secretary,  
Listing Department,  
BSE Limited,  
Floor 25, P J Towers,  
Dalal Street,  
MUMBAI- 400001

**Sub: Outcome of 2<sup>nd</sup> /2017-18 Board Meeting and Submission of Audited Financial Results & Statement of Assets & Liabilities for the quarter and year ended 31.03.2017**

**SCRIP CODE: 530207**

Dear Sir,

In terms of Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the 2<sup>nd</sup> / 2017-18 meeting of the Board of Directors of the Company held today, the 29<sup>th</sup> May, 2017 at its registered office, wherein the following businesses were transacted:


1. Considered and approved statement of standalone financial results along with Statement of Assets & Liabilities for the quarter and year ended 31<sup>st</sup> March, 2017, copies whereof along with Audit Report for standalone results and declaration by the Chief Financial Officer of the Company in terms of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed herewith.
2. The Board accepted the shifting of registered office address from C- 64, Lajpat Nagar- I, New Delhi- 110024 to 4/4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi- 110002.

The meeting of the Board of Directors was commenced at 03.00 P.M. and concluded at 05.30 P.M.

You are requested to take above on record.

Thanking you,

For BRAWN BIOTECH LIMITED

  
(Mamta Surkali)  
Company Secretary

Encl.: As above



**BRAWN BIOTECH LTD.**

(Formerly Known as Brawn Pharmaceuticals Ltd.)

...for better life

Regd. Office : C-64, LAJPAT NAGAR-1, NEW DELHI-110024 TEL.: 91-11-29815331 Email : legal@brawnlabs.com Website : www.brawnlabs.com

Export Office : OLD DELHI STOCK EXCHANGE BUILDING 4/4B, ASAF ALI ROAD, NEW DELHI-110002 (INDIA) TEL.: 011-32911528, 32911529 FAX: 011-23275208  
Email: export@brawnlabs.com

Corporate Office : Plot No. - 30, Sector - 33 Near Hero Honda Factory, Gurgaon (Haryana) 122001 TEL.: 0124-4666152, 4222462, E-mail: admin@brawnlabs.com

Works : 13, NEW INDUSTRIAL TOWNSHIP, FARIDABAD-121001 (HR) TEL.: 0129-3290659 / 3290738 E-mail : plant\_fbd@brawnlabs.com



**BRAWN**



4996A

CIN NO.: L74899DL1985PLC022468

To,

Date: 29-05-2017

The Secretary,  
Listing Department,  
BSE Limited,  
Floor 25, P J Towers,  
Dalal Street,  
MUMBAI- 400001

**SUB: DECLARATION**

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we do hereby confirm that M/s. Rajiv Udai & Associates, Chartered Accountants, the Statutory Auditors of the Company have issued an Audit Report with unmodified opinion(s) on the Audited Standalone Financial Results of the Company for the quarter and year ended on 31<sup>st</sup> March, 2017.

For **BRAWN BIOTECH LIMITED**

**RATI GARG**  
(CHIEF FINANCIAL OFFICER)



**BRAWN BIOTECH LTD.**

(Formerly Known as Brawn Pharmaceuticals Ltd.)

*...for better life*

Regd. Office : C-64, LAJPAT NAGAR-1, NEW DELHI-110024 TEL.: 91-11-29815331 Email : legal@brawnlab.com Website : www.brawnlab.com

Export Office : OLD DELHI STOCK EXCHANGE BUILDING 4/4B, ASAF ALI ROAD, NEW DELHI-110002 (INDIA) TEL.: 011-32911528, 32911529 FAX: 011-23275208  
Email: export@brawnlab.com

Corporate Office : Plot No. - 30, Sector - 33 Near Hero Honda Factory, Gurgaon (Haryana) 122001 TEL.: 0124-4666152, 4222462, E-mail: admin@brawnlab.com

Works : 13, NEW INDUSTRIAL TOWNSHIP, FARIDABAD-121001 (HR) TEL.: 0129-3290659 / 3290738 E-mail : plant\_fbd@brawnlab.com



Auditor's Report on Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**To Board of Directors of Brawn Biotech Limited**

We have audited the quarterly financial results of **Brawn Biotech Limited** for the quarter ended **31<sup>st</sup> March 2017** and the year to date results for the period **01<sup>st</sup> April 2016 to 31<sup>st</sup> March 2017** attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management.

Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25 / Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.


We conducted our audit in accordance with the auditing standards generally accepted in India.

Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give a true and fair view of the net profit/ and other financial information for the quarter ended **31<sup>st</sup> March 2017** as well as the year to date results for the period from **01<sup>st</sup> April 2016 to 31<sup>st</sup> March 2017**.

**For Rajiv Udai & Associates**  
**Chartered Accountants**  
**Firm Registration No. 18764N**

  
(Rajeev Jain)  
Partner  
(099767)



Place: Delhi  
Date: 29-05-2017



# BRAWN



2CB32

CIN NO.: L74899DL1985PLC022468

BRAWN BIOTECH LIMITED

(formerly known as Brawn Pharmaceuticals Limited)

CIN: L74899DL1985PLC022468

REGD. OFFICE: C-64, LAJPAT NAGAR-I, NEW DELHI-110024

Statement of Standalone Audited Financial Results for the quarter & year ended 31st March, 2017

| PART I         |   |                              |   |   |  |                                   |
|----------------|---|------------------------------|---|---|--|-----------------------------------|
| (Rs. in Lakhs) |   |                              |   |   |  |                                   |
|                | Particulars   | 3 months ended<br>31/03/2017 | Preceding<br>3 months ended<br>31/12/2016 | Corresponding<br>3 months ended<br>31/03/2016 in the<br>previous year | Year to date figures<br>for current period<br>ended 31/03/2017 | Previous Year<br>ended 31/03/2016 |
|                |   | Audited                      | Unaudited                                 | Audited   | Audited  | Audited                           |
| 1              | Income from operations  |                              |   |   |  |                                   |
|                | Net sales/ income from operations (Net of excise duty)  | 1,623.54                     | 1,607.25                                  | 1,138.18  | 5,960.58   | 4,562.24                          |
|                | Other operating income  | 21.17                        | 24.49                                     | 18.19   | 94.10  | 126.14                            |
|                | <b>Total income from operations (net)</b>   | <b>1,644.71</b>              | <b>1,631.74</b>                           | <b>1,156.37</b>   | <b>6,054.68</b>  | <b>4,688.38</b>                   |
| 2              | Expenses  |                              |   |   |  |                                   |
|                | (a) Cost of materials consumed  | -                            | -   | -   | -  | -                                 |
|                | (b) Purchases of stock-in-trade   | 1,387.14                     | 1,433.15                                  | 959.27  | 5,206.74   | 3,998.86                          |
|                | (c) Changes in inventories of finished goods, work-in- progress and stock-in- trade             | (2.53)                       | (7.74)                                    | 16.61   | 12.32  | 53.24                             |
|                | (d) Employee benefits expense   | 58.90                        | 45.16                                     | 59.31   | 198.19   | 186.18                            |
|                | (e) Depreciation and amortisation expenses  | 0.78                         | 0.82                                      | 0.56  | 3.11   | 3.32                              |
|                | (f) Other expenses  | 177.64                       | 119.86                                    | 111.59  | 514.24   | 307.52                            |
|                | <b>Total expenses</b>   | <b>1,621.92</b>              | <b>1,591.24</b>                           | <b>1,147.34</b>   | <b>5,934.59</b>  | <b>4,549.12</b>                   |
| 3              | Profit / (Loss) from operation before other income, finance costs and exceptional items (1-2)   | 22.79                        | 40.50                                     | 9.03  | 120.09   | 139.26                            |
| 4              | Other income  | 3.89                         | -   | 0.97  | 4.44   | 0.80                              |
| 5              | Profit / (Loss) from ordinary activities before finance costs and exceptional items (3+4)       | 26.68                        | 40.50                                     | 10.00   | 124.53   | 140.06                            |
| 6              | Finance Cost  | 4.68                         | 0.78                                      | 0.45  | 6.55   | 9.57                              |
| 7              | Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5+6) | 21.99                        | 39.72                                     | 9.55  | 117.97   | 130.49                            |
| 8              | Exceptional items   | -                            | -   | -   | 57.60  | -                                 |
| 9              | Profit / (Loss) from ordinary activities before tax (7+8)                                       | 21.99                        | 39.72                                     | 9.55  | 175.57   | 130.49                            |
| 10             | Tax expense   | (1.17)                       | 13.40                                     | 27.49   | 36.33  | 35.52                             |
| 11             | Net Profit / (Loss) from ordinary activities after tax (9 + 10)                                 | 23.16                        | 26.31                                     | (17.94)   | 139.24   | 94.97                             |
| 12             | Extraordinary items (net of tax expense)  | -                            | -   | -   | -  | -                                 |
| 13             | Net Profit / (Loss) for the period (11+12)  | 23.16                        | 26.31                                     | (17.94)   | 139.24   | 94.97                             |
| 14             | Paid-up equity share capital<br>(Face Value of the Share shall be indicated)                    | 300.03                       | 300.03                                    | 300.03  | 300.03   | 300.03                            |
| 15             | Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year         | 337.65                       | 368.64                                    | 252.00  | 337.65   | 252.57                            |
| 16 i           | Earnings per share (before extraordinary items) (not annualised): in Rs.                        |                              |   |   |  |                                   |
|                | (a) Basic   | 0.77                         | 0.88                                      | (0.60)  | 4.64   | 3.17                              |
|                | (b) Diluted   | 0.77                         | 0.88                                      | (0.60)  | 4.64   | 3.17                              |
| 16 ii          | Earnings per share (after extraordinary items) (not annualised): in Rs.                         |                              |   |   |  |                                   |
|                | (a) Basic   | 0.77                         | 0.88                                      | (0.60)  | 4.64   | 3.17                              |
|                | (b) Diluted   | 0.77                         | 0.88                                      | (0.60)  | 4.64   | 3.17                              |

**Notes:**

- The above results have been audited by the Statutory Auditors and reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 29.05.2017
- The Board has recommended a final dividend of Rs. 1.5/- per equity share of face value of Rs. 10/- each for the year ended 31st March 2017 subject to approval of shareholders in the Annual General Meeting of the Company.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Accounting Standard-17 dealing with Segment Reporting.
- The figures for the quarter ended 31st March 2017 and 31st March 2016 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the 3rd quarter of the relevant financial year.
- Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board  
For Brawn Biotech Limited


*Brij Raj Gupta*  
Managing Director  
DIN NO. 00974969



Place: New Delhi

Date: 29.05.2017 **BRAWN BIOTECH LTD.**  
(Formerly Known as Brawn Pharmaceuticals Ltd.)

Regd. Office : C-64, LAJPAT NAGAR-1, NEW DELHI-110024 TEL.: 91-11-29815331 Email : legal@brawnlabs.com Website : www.brawnlabs.com  
Export Office : OLD DELHI STOCK EXCHANGE BUILDING 4/4B, ASAF ALI ROAD, NEW DELHI-110002 (INDIA) TEL.: 011-32911528, 32911529 FAX: 011-23275208 Email: export@brawnlabs.com  
Corporate Office : Plot No. - 30, Sector - 33 Near Hero Honda Factory, Gurgaon (Haryana) 122001 TEL.: 0124-4666152, 4222462, E-mail: admin@brawnlabs.com  
Works : 13, NEW INDUSTRIAL TOWNSHIP, FARIDABAD-121001 (HR) TEL.: 0129-3290659 / 3290738 E-mail : plant\_fbd@brawnlabs.com

**BRAWN****BRAWN BIOTECH LIMITED**

(Formerly Known as Brawn Pharmaceuticals Limited)

Regd Office: C-64, Lajpat Nagar-1, New Delhi 110024



CIN NO.: L74899DL1985PLC022468

**Standalone Audited Statement of Assets & Liabilities**

(Rs. in Lakhs)

|          | Particulars                                  | As at 31/03/2017 | As at 31/03/2016 |
|----------|--|------------------|------------------|
| <b>A</b> | <b>EQUITY AND LIABILITIES</b>                |                  |                  |
| <b>1</b> | <b>Shareholders' funds</b>                   |                  |                  |
|          | (a) Share Capital                            | 300.03           | 300.03           |
|          | (b) Reserves and Surplus                     | 337.65           | 252.57           |
|          | <b>Sub-Total - Shareholders' funds</b>       | <b>637.68</b>    | <b>552.60</b>    |
| <b>2</b> | <b>Non-current liabilities</b>               |                  |                  |
|          | (a) Long Term Borrowings                     | -                | 4.84             |
|          | (b) Deferred Tax Liabilities (net)           | -                | -                |
|          | (c) Long Term Provisions                     | 9.90             | 7.77             |
|          | <b>Sub-Total - Non-current liabilities</b>   | <b>9.90</b>      | <b>12.61</b>     |
| <b>3</b> | <b>Current liabilities</b>                   |                  |                  |
|          | (a) Short Term Borrowings                    | -                | -                |
|          | (b) Trade Payables                           | 681.92           | 495.26           |
|          | (c) Other Current Liabilities                | 189.52           | 175.05           |
|          | (d) Short Term Provisions                    | 184.03           | 159.44           |
|          | <b>Sub-Total - Current liabilities</b>       | <b>1,055.48</b>  | <b>829.75</b>    |
|          | <b>TOTAL - EQUITY AND LIABILITIES ASSETS</b> | <b>1,703.06</b>  | <b>1,394.96</b>  |
| <b>B</b> | <b>ASSETS</b>                                |                  |                  |
| <b>1</b> | <b>Non-current assets</b>                    |                  |                  |
|          | (a) Fixed assets                             | 25.16            | 23.68            |
|          | (b) Non-Current Investments                  | -                | 3.00             |
|          | (c) Deferred Tax Assets (net)                | 4.72             | 2.13             |
|          | (d) Long Term Loans and Advances             | 10.60            | 8.17             |
|          | (e) Other non Current Assets                 | -                | 268.16           |
|          | <b>Sub-Total - Non-current assets</b>        | <b>40.47</b>     | <b>305.15</b>    |
| <b>2</b> | <b>Current assets</b>                        |                  |                  |
|          | (a) Inventories                              | 37.22            | 49.54            |
|          | (b) Trade Receivables                        | 1,302.35         | 920.23           |
|          | (c) Cash and Cash Equivalents                | 199.93           | 17.37            |
|          | (d) Short Term Loans and Advances            | 123.08           | 102.67           |
|          | (e) Other Current Assets                     | -                | -                |
|          | <b>Sub-Total - Current assets</b>            | <b>1,662.58</b>  | <b>1,089.81</b>  |
|          | <b>TOTAL - ASSETS</b>                        | <b>1,703.06</b>  | <b>1,394.96</b>  |

For and on behalf of Board  
For Brawn Biotech LimitedBrij Raj Gupta  
Managing Director  
DIN NO. 00974969

...for better life

Place: New Delhi

Date: 29.05.2017

**BRAWN BIOTECH LTD.**

(Formerly Known as Brawn Pharmaceuticals Ltd.)

Regd. Office : C-64, LAJPAT NAGAR-1, NEW DELHI-110024 TEL.: 91-11-29815331 Email : legal@brawnbiotech.com Website : www.brawnbiotech.com

Export Office : OLD DELHI STOCK EXCHANGE BUILDING 4/4B, ASAF ALI ROAD, NEW DELHI-110002 (INDIA) TEL.: 011-32911528, 32911529 FAX: 011-23275208  
Email: export@brawnbiotech.com

Corporate Office : Plot No. - 30, Sector - 33 Near Hero Honda Factory, Gurgaon (Haryana) 122001 TEL.: 0124-4666152, 422246 E-mail: admin@brawnbiotech.com

Works : 13, NEW INDUSTRIAL TOWNSHIP, FARIDABAD-121001 (HR) TEL.: 0129-3290659 / 3290738 E-mail : plant\_fbd@brawnbiotech.com